Among significant research news last week, US biotech Allakos reported that it was dropping development of its urticaria ...

A milk allergy and lactose intolerance can cause similar symptoms after consuming dairy, but they are not the same. Here are ...

Celldex Therapeutics , Inc. (NASDAQ:CLDX), a biopharmaceutical company focused on developing innovative therapies for ...

New research published in the journal Science uncovers how scratching aggravates inflammation and swelling in a mouse model ...

Zevra to receive a 2025 New Treatment Award for MIPLYFFA™ at the 21st Annual WORLDSymposiumEight abstracts discussing data and clinical ...

Celldex Therapeutics , Inc. (NASDAQ:CLDX), with a market capitalization of $1.72 billion, is a biopharmaceutical company focused on developing innovative therapies for challenging diseases, with its ...

Scratching an itchy rash really does make it worse. Now we know why, thanks to new research that uncovers how scratching aggravates inflammation and swelling in a mouse model of a type of eczema ...

BioAge scrapped the drug at the center of its $198 million initial public offering last year. Elsewhere, Akero and 89bio raised $600 million combined and Allakos laid off staff.

The following is a summary of “Off-label use of biologics in urticarial vasculitis: a European retrospective cohort study,” ...

Leerink Partners analyst Thomas Smith has reiterated their neutral stance on ALLK stock, giving a Hold rating on January 27.Invest with ...

A year after reducing half of its workforce, Allakos will downsize to just 15 employees as it halts the development of AK006.

A Bay Area biotech firm is laying off 75% of its staff following a flopped clinical trial. Allakos, based in San Carlos, ...